1
|
Jelinek T, Schade Larsen C, Siikamäki H, Myrvang B, Chiodini P, Gascón J, Visser L, Kapaun A, Just-Nübling G. European cluster of imported falciparum malaria from Gambia. Euro Surveill 2008. [DOI: 10.2807/ese.13.51.19077-en] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A cluster of 56 patients returning from Gambia with falciparum malaria has been noted in several countries of the European Union since September this year. TropNetEurop, the European Network on Imported Infectious Disease Surveillance, collected and reported the cases. Lack of awareness and, consequently, of prophylactic measures against malaria were apparent in the majority of patients.
Collapse
Affiliation(s)
- T Jelinek
- Berlin Centre for Travel and Tropical Medicine, Berlin, Germany
| | - C Schade Larsen
- Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
| | - H Siikamäki
- Helsinki University Central Hospital, Division of Infectious Diseases, Department of Medicine, Helsinki, Finland
| | - B Myrvang
- Department of Infectious Diseases, Ullevaal University Hospital, Oslo, Norway
| | - P Chiodini
- Hospital for Tropical Diseases and Health Protection Agency Malaria Reference Laboratory, London School of Hygiene and Tropical Medicine, United Kingdom
| | - J Gascón
- International Health Centre, Hospital Clinic, Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain
| | - L Visser
- Department of Infectious Disease, Section Travel Medicine, Leiden University Medical Centre, Leiden, the Netherlands
| | - A Kapaun
- Section Clinical Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany
- Department of Infectious Diseases, Ullevaal University Hospital, Oslo, Norway
| | - G Just-Nübling
- Klinik II, Centre for infectious and tropical diseases , J.W. Goethe University, Frankfurt/Main, Germany
| |
Collapse
|
2
|
Jelinek T, Schade Larsen C, Siikamäki H, Myrvang B, Chiodini P, Gascon J, Visser L, Kapaun A, Just-Nübling G. European cluster of imported falciparum malaria from Gambia. Euro Surveill 2008; 13:19077. [PMID: 19094917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
A cluster of 56 patients returning from Gambia with falciparum malaria has been noted in several countries of the European Union since September this year. TropNetEurop, the European Network on Imported Infectious Disease Surveillance, collected and reported the cases. Lack of awareness and, consequently, of prophylactic measures against malaria were apparent in the majority of patients.
Collapse
Affiliation(s)
- T Jelinek
- Berlin Centre for Travel and Tropical Medicine, Berlin, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Rahim Z, Storla D, Shahzada Khan M, Mannsåker T, Myrvang B, Bjune G, Dahle U, Sola C, van Soolingen D, Suzuki Y, van der Zanden AG. Prevalence of Different Phylogenetic Clades of Mycobacterium tuberculosis in Urban and Rural Areas Bangladesh. Int J Infect Dis 2008. [DOI: 10.1016/j.ijid.2008.05.910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
4
|
|
5
|
Abstract
The subjective health status of hepatitis C patients has been relatively poorly studied. By using the Short Form 36 (SF-36), health-related quality of life (HRQOL) was assessed in a group of 42 hepatitis C patients. In all nine scales examined, the scores were generally low, and present drug use and being single were associated with especially large reductions in HRQOL. Compared with the Norwegian norms, scores were lower across all nine scales and significantly lower in eight. The study showed that the hepatitis C patients had definite reductions in HRQOL, but the impairment could not be fully explained by their hepatitis. Different non-viral factors such as drug use and marital status significantly influenced the results. This underlines the importance of taking other factors into account when studying the health status of hepatitis C patients.
Collapse
Affiliation(s)
- S Gjeruldsen
- Department of Infectious Diseases, Ullevål University Hospital, Oslo, Norway.
| | | | | | | |
Collapse
|
6
|
Mühlberger N, Jelinek T, Gascon J, Probst M, Zoller T, Schunk M, Beran J, Gjørup I, Behrens RH, Clerinx J, Björkman A, McWhinney P, Matteelli A, Lopez-Velez R, Bisoffi Z, Hellgren U, Puente S, Schmid ML, Myrvang B, Holthoff-Stich ML, Laferl H, Hatz C, Kollaritsch H, Kapaun A, Knobloch J, Iversen J, Kotlowski A, Malvy DJM, Kern P, Fry G, Siikamaki H, Schulze MH, Soula G, Paul M, Prat JGI, Lehmann V, Bouchaud O, Cunha SD, Atouguia J, Boecken G. Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J 2004; 3:5. [PMID: 15003128 PMCID: PMC385246 DOI: 10.1186/1475-2875-3-5] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2003] [Accepted: 03/08/2004] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Plasmodium vivax is the second most common species among malaria patients diagnosed in Europe, but epidemiological and clinical data on imported P. vivax malaria are limited. The TropNetEurop surveillance network has monitored the importation of vivax malaria into Europe since 1999. OBJECTIVES To present epidemiological and clinical data on imported P. vivax malaria collected at European level. MATERIAL AND METHODS Data of primary cases of P. vivax malaria reported between January 1999 and September 2003 were analysed, focusing on disease frequency, patient characteristics, place of infection, course of disease, treatment and differences between network-member countries. RESULTS Within the surveillance period 4,801 cases of imported malaria were reported. 618 (12.9%) were attributed to P. vivax. European travellers and immigrants were the largest patient groups, but their proportion varied among the reporting countries. The main regions of infection in descending order were the Indian subcontinent, Indonesia, South America and Western and Eastern Africa, as a group accounting for more than 60% of the cases. Regular use of malaria chemoprophylaxis was reported by 118 patients. With 86 (inter-quartile range 41-158) versus 31 days (inter-quartile range 4-133) the median symptom onset was significantly delayed in patients with chemoprophylaxis (p < 0.0001). Common complaints were fever, headache, fatigue, and musculo-skeletal symptoms. All patients survived and severe clinical complications were rare. Hospitalization was provided for 60% and primaquine treatment administered to 83.8% of the patients, but frequencies varied strongly among reporting countries. CONCLUSIONS TropNetEurop data can contribute to the harmonization of European treatment policies.
Collapse
Affiliation(s)
- N Mühlberger
- Institute of Tropical Medicine, Humboldt University, Berlin, Germany
| | - T Jelinek
- Institute of Tropical Medicine, Humboldt University, Berlin, Germany
| | - J Gascon
- Secció Medicina Tropical, Hospital Clinic Barcelona – IDIBAPS., Barcelona, Spain
| | - M Probst
- Department of Medicine (Infectious Diseases), Charité, Humboldt University, Berlin, Germany
| | - T Zoller
- Department of Medicine (Infectious Diseases), Charité, Humboldt University, Berlin, Germany
| | - M Schunk
- Department of Infectious Diseases and Tropical Medicine, University of Munich, Germany
| | - J Beran
- Department of Infectious Diseases, University Hospital Hradec Králové, Czech Republic
| | - I Gjørup
- Department of Infectious Diseases, Rigshospitalet, University of Copenhagen; Denmark
| | - RH Behrens
- Hospital for Tropical Diseases, London, UK
| | - J Clerinx
- Clinical Services, Prins Leopold Instituut voor Tropische Geneeskunde, Antwerp; Belgium
| | - A Björkman
- Department of Medicine, Unit of Infectious Diseases, Karolinska Institute, Stockholm, Sweden
| | - P McWhinney
- Infection and Tropical Medicine, Bradford Royal Infirmary, Bradford, UK
| | - A Matteelli
- Clinica di Malattie Infettive e Tropicali, Universitá di Brescia, Italy
| | - R Lopez-Velez
- Infectious Diseases–Microbiology Department, Tropical Medicine & Clinical Parasitology Unit, Hospital Ramon y Cajal, Madrid, Spain
| | - Z Bisoffi
- Centro per le Malattie Tropicali, Ospedale S. Cuore, Negrar Verona, Italy
| | - U Hellgren
- Division of Infectious Diseases, Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden
| | - S Puente
- Sección de Medicina Tropical-Servicio de Enfermedades Infecciosas, Hospital Carlos III- Instituto de Salud Carlos III, Madrid, Spain
| | - ML Schmid
- Department of Infection & Tropical Medicine, Newcastle General Hospital, Newcastle- upon-Tyne, UK
| | - B Myrvang
- Department of Infectious Diseases, Ullevaal University Hospital, Oslo, Norway
| | | | - H Laferl
- 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Kaiser-Franz-Josef-Spital der Stadt Wien, Vienna, Austria
| | - C Hatz
- Swiss Tropical Institute, Basel, Switzerland
| | - H Kollaritsch
- Abteilung fur spezifische Prophylaxe und Tropenmedizin am Institut für Pathophysiologie, University of Vienna, Austria
| | - A Kapaun
- Institut für Tropenhygiene und öffentliches Gesundheitswesen, Universität Heidelberg, Germany
| | - J Knobloch
- Institut für Tropenmedizin, Universitätsklinikum Tübingen, Germany
| | - J Iversen
- Department of Infectious Diseases, Hvidovre Hospital, Hvidovre, Denmark
| | - A Kotlowski
- Department of Tropical Medicine and Epidemiology, Medical University of Gdansk, Interfacultary Institute of Maritime and Tropical Medicine in Gdynia, Poland
| | - DJM Malvy
- Hôpital St André-CHU, Bordeaux, France
| | - P Kern
- Sektion Infektiologie und Klinische Immunologie, Universität Ulm, Germany
| | - G Fry
- Tropical Medical Bureau, Dublin, Ireland
| | - H Siikamaki
- Department of Medicine, Division of Infectious Diseases, Helsinki University Central Hospital, Helsinki, Finland
| | - MH Schulze
- 2. Klinik für Innere Medizin, Städtische Kliniken "St. Georg", Leipzig, Germany
| | - G Soula
- Department of Infectious and Tropical Diseases, Hopital Nord CHU, Marseille, France
| | - M Paul
- Department and Clinic of Tropical and Parasitic Diseases, Karol Marcinkowski University of Medical Sciences, Poznan, Poland
| | - J Gómez i Prat
- Unitat de Malalties Tropicals, Importades i Vacunacions Internationales, Institut Català de la Salut, Barcelona, Spain
| | - V Lehmann
- Centre for Tropical Medicine and Imported Infectious Diseases, Haukeland University Hospital, Bergen, Norway
| | - O Bouchaud
- Consultation de médecine tropicale, Hôpital Avicenne, Bobigny, France
| | - S da Cunha
- Consulta de Medicina do Viajante, Departamento de Doenças Infecciosas, Hospital Universitário, Coimbra, Portugal
| | - J Atouguia
- Instituto de Higiena e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal
| | - G Boecken
- The German Navy Institute for Maritime Medicine, Center for Applied Tropical Medicine and Infectious Diseases Epidemiology, Kronshagen, Germany
| |
Collapse
|
7
|
Jensenius M, Fournier PE, Hellum KB, Wesslén L, Caruso G, Priø T, Løhne K, Vene S, Raoult D, Myrvang B. Sequential changes in hematologic and biochemical parameters in African tick bite fever. Clin Microbiol Infect 2003; 9:678-83. [PMID: 12925109 DOI: 10.1046/j.1469-0691.2003.00713.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To evaluate the sequential changes and to estimate the frequencies of abnormalities in some commonly measured biological variables in patients with African tick bite fever (ATBF), an emerging spotted fever group (SFG) rickettsiosis in international travelers to rural sub-Saharan Africa. METHODS A study was done of hemoglobin, total leukocyte count, absolute lymphocyte count, blood platelet count and serum levels of C-reactive protein (S-CRP), alanine aminotransferase (S-ALAT), aspartate aminotransferase, lactic dehydrogenase, gamma-glutamyl transferase, alkaline phosphatase, bilirubin, sodium and creatinine during the first two weeks of illness and prior to the institution of antirickettsial therapy in 108 patients with travel-associated ATBF. RESULTS There were significant falls in mean total leukocyte count, mean absolute lymphocyte count, and mean platelet count, and significant increases in mean S-CRP and S-ALAT. During the first ten days of illness, elevated S-CRP, lymphopenia and elevated S-ALAT were detected in 91.7%, 73.3% and 40.7% of patients, respectively. Most abnormalities were mild. For 55 patients who underwent both S-CRP and absolute lymphocyte count determination, at least one parameter was abnormal in 52 (94.5%) patients. CONCLUSIONS The sequential changes in many biological parameters during the acute phase of ATBF mimic those reported in other SFG rickettsioses. Mild abnormalities are frequent, with increased S-CRP and lymphopenia being the two most consistent findings.
Collapse
Affiliation(s)
- M Jensenius
- Department of Internal Medicine, Department of Clinical Chemistry, Aker University Hospital, Oslo, Norway.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Grobusch MP, Mühlberger N, Jelinek T, Bisoffi Z, Corachán M, Harms G, Matteelli A, Fry G, Hatz C, Gjørup I, Schmid ML, Knobloch J, Puente S, Bronner U, Kapaun A, Clerinx J, Nielsen LN, Fleischer K, Beran J, da Cunha S, Schulze M, Myrvang B, Hellgren U. Imported schistosomiasis in Europe: sentinel surveillance data from TropNetEurop. J Travel Med 2003; 10:164-9. [PMID: 12757691 DOI: 10.2310/7060.2003.35759] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
BACKGROUND Schistosomiasis is a major parasitic disease, increasingly imported into temperate climates by immigrants from and travelers to endemic areas. METHOD To generate valid data on imported infectious diseases to Europe and to recognize trends over time, the European Network on Imported Infectious Diseases Surveillance (TropNetEurop) was founded in 1999. Three hundred and thirty-three reports of schistosomiasis were analyzed for epidemiologic and clinical features. RESULTS Male patients accounted for 64% of all cases. The average age of all patients was 29.5 years. The majority of patients were of European origin (53%). Europeans traveled predominantly for tourism (52%). Main reasons for travel for people from endemic areas were immigration and refuge (51%) and visits to relatives and friends (28%). The majority of infections were acquired in Africa; 92 infections were clearly attributable to Schistosoma haematobium, 130 to Schistosoma mansoni, and 4 to Schistosoma intercalatum. Praziquantel was the only treatment used. No deaths were recorded. CONCLUSION TropNetEurop sentinel provides valuable epidemiologic and clinical data on imported schistosomiasis to Europe.
Collapse
Affiliation(s)
- M P Grobusch
- Institut für Tropenmedizin, Universitätsklinikum Tübingen, Tübingen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Mühlberger N, Jelinek T, Behrens RH, Gjørup I, Coulaud JP, Clerinx J, Puente S, Burchard G, Gascon J, Grobusch MP, Weitzel T, Zoller T, Kollaritsch H, Beran J, Iversen J, Hatz C, Schmid ML, Björkman A, Fleischer K, Bisoffi Z, Guggemos W, Knobloch J, Matteelli A, Schulze MH, Laferl H, Kapaun A, McWhinney P, Lopez-Velez R, Fätkenheuer G, Kern P, Zieger BW, Kotlowski A, Fry G, Cuadros J, Myrvang B. Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. Clin Infect Dis 2003; 36:990-5. [PMID: 12684911 DOI: 10.1086/374224] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2002] [Accepted: 01/16/2003] [Indexed: 11/03/2022] Open
Abstract
Previous studies have indicated that age is a risk factor for severe falciparum malaria in nonimmune patients. The objectives of this study were to reevaluate previous findings with a larger sample and to find out how strongly clinical outcomes for elderly patients differ from those for younger patients. Results of adjusted analyses indicated that the risks of death due to falciparum malaria, of experiencing cerebral or severe disease in general, and of hospitalization increased significantly with each decade of life. The case-fatality rate was almost 6 times greater among elderly patients than among younger patients, and cerebral complications occurred 3 times more often among elderly patients. Antimalarial chemoprophylaxis was significantly associated with a lower case-fatality rate and a lower frequency of cerebral complications. Women were more susceptible to cerebral complications than were men. Our study provides evidence that falciparum malaria is more serious in older patients and demonstrates that clinical surveillance networks are capable of providing quality data for investigation of rare events or diseases.
Collapse
Affiliation(s)
- N Mühlberger
- Department of Infectious Diseases and Tropical Medicine, University of Munich, Munich, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Jelinek T, Mühlberger N, Harms G, Corachán M, Grobusch MP, Knobloch J, Bronner U, Laferl H, Kapaun A, Bisoffi Z, Clerinx J, Puente S, Fry G, Schulze M, Hellgren U, Gjørup I, Chalupa P, Hatz C, Matteelli A, Schmid M, Nielsen LN, da Cunha S, Atouguia J, Myrvang B, Fleischer K. Epidemiology and clinical features of imported dengue fever in Europe: sentinel surveillance data from TropNetEurop. Clin Infect Dis 2002; 35:1047-52. [PMID: 12384837 DOI: 10.1086/342906] [Citation(s) in RCA: 129] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2002] [Revised: 06/06/2002] [Indexed: 11/03/2022] Open
Abstract
Travelers have the potential both to acquire and to spread dengue virus infection. The incidence of dengue fever (DF) among European travelers certainly is underestimated, because few centers use standardized diagnostic procedures for febrile patients. In addition, DF is currently not reported in most European public health systems. Surveillance has commenced within the framework of a European Network on Imported Infectious Disease Surveillance (TropNetEurop) to gain information on the quantity and severity of cases of dengue imported into Europe. Descriptions of 294 patients with DF were analyzed for epidemiological information and clinical features. By far the most infections were imported from Asia, which suggests a high risk of DF for travelers to that region. Dengue hemorrhagic fever occurred in 7 patients (2.4%) all of whom recovered. Data reported by member sites of the TropNetEurop can contribute to understanding the epidemiology and clinical characteristics of imported DF.
Collapse
Affiliation(s)
- T Jelinek
- Department of Infectious Diseases and Tropical Medicine, University of Munich, 80802 Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Abstract
In a group of 159 drug addicts with acute hepatitis B in the 1970s there were no fatalities. During an observation period of about 25 years, 51 of the 159 died of various causes, but no deaths could be attributed to the hepatitis B infection. From 1998 to 2001, a follow-up examination of 53 of the 108 patients still alive, none of the 53 had a chronic hepatitis B virus infection. Fifteen out of thirty-five patients who had completely stopped using narcotics claimed that hospitalisation for acute hepatitis B had been an important factor in their decision to quit drugs.
Collapse
Affiliation(s)
- S Gjeruldsen
- Department of Infectious Diseases, Ullevål University Hospital, Oslo, Norway
| | | |
Collapse
|
12
|
Distante S, Bjøro K, Hellum KB, Myrvang B, Berg JP, Skaug K, Raknerud N, Bell H. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002; 22:269-75. [PMID: 12100578 DOI: 10.1046/j.0106-9543.2002.01672.x] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND/AIM Previous studies have indicated that response to interferon therapy is inversely proportional to the amount of body iron stores. We have studied the relationship between serum ferritin, transferrin saturation, liver iron, presence of HFE-C282Y gene mutation and response to treatment in patients with chronic hepatitis C infection. METHODS Two hundred and fifty-six naive, HCV-RNA positive patients (60% males, median age 38 years, range 21-70) were treated with interferon and ribavirin for 6 months. Iron indices and the presence of the C282Y mutation were measured. In 242 (94%) patients iron deposition were determined by Perls staining method. Patients with negative HCV-RNA at 6 months after the end of treatment were defined as sustained viral responders. RESULTS Non-responders (n = 127) had significantly higher median s-ferritin values compared with sustained viral responders (130 microg/L vs. 75 microg/L P < 0.001). There was no difference in transferrin saturation among the two response groups. Only 23% (4/7) of patients with Perls grade 1 in liver biopsies responded to treatment vs. 54% (122/225) patients without iron deposition (P = 0.02), however, 10/13-non-responders had HCV genotype one. Two patients (0.8%) were homozygous for the C282Y mutation, 36 patients were heterozygous (14%). Among mutation carriers 26/38 achieved sustained response compared with 102/216 non-carriers (68% vs. 48%, P = 0.02). In a multivariate analysis s-ferritin (P = 0.030) and C282Y carrier status (P = 0.012) remained independent predict of sustained response. CONCLUSIONS Raised s-ferritin values predicate non-response to interferon-ribavirin therapy in hepatitis C patients. Response rate in C282Y mutation carriers seems greater than in non-carriers.
Collapse
Affiliation(s)
- S Distante
- Hepatology Unit, Department of Medicine, Aker University Hospital, Oslo, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Dalgard O, Bjøro K, Hellum K, Myrvang B, Bjøro T, Haug E, Bell H. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002; 251:400-6. [PMID: 11982739 DOI: 10.1046/j.1365-2796.2002.00974.x] [Citation(s) in RCA: 82] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
OBJECTIVES Treatment of chronic hepatitis C with interferon-alpha (IFN-alpha) may induce thyroid disorders. We evaluated whether this risk is related to the dosage of IFN-alpha or the virological treatment response. Other possible risk factors as well as the evolution of the thyroid abnormalities were also studied. METHODS In this prospective trial (n=254), thyroid-stimulating hormone (TSH), free thyroxin (fT4) and thyroid peroxidase autoantibodies were measured before, during and after treatment for hepatitis C virus (HCV). The patients were randomized to either induction therapy [IFN-alpha 6 million units (MIU) daily for 4 weeks and 3 MIU 3/7 days for 22 weeks] or conventional therapy [IFN-alpha 3 MIU 3/7 days for 26 weeks]. In addition, all patients received ribavirin (1000 or 1200 mg) daily. Sustained virological response was defined as loss of detectable HCV RNA at 6 months follow-up. Thyroid dysfunction was defined as TSH level below or above the normal range (0.2-4.5 MIU L-1). RESULTS Biochemical thyroid dysfunction developed in 30 (11.8%) of 254 patients. Hypothyroidism (TSH > 4.5 MIU L-1) was seen in 20 and hyperthyroidism (TSH < 0.2 MIU L-1) in 10 patients. Nine of the 30 patients developed symptomatic thyroid disease and HCV treatment was discontinued because of thyroid dysfunction in three of these patients. Thyroid dysfunction occurred in 15 (11.7%) of 128 patients who received high-dose IFN-alpha induction therapy as compared with 15 (11.9%) of 126 patients who received conventional IFN-alpha therapy (P=0.96). Amongst 231 patients who completed all 6 months of HCV treatment, a sustained virological response was obtained in 19 (66%) of 29 with thyroid dysfunction and 109 (54%) of 202 without (P=0.24). By multivariate analysis female gender and Asian origin were independent predictors of developing biochemical thyroid dysfunction (P < 0.01). CONCLUSION Thyroid dysfunction occurred in 11.8% of patients treated for chronic hepatitis C with IFN-alpha and ribavirin. Neither the IFN-alpha dosage nor the virological response to treatment were related to the incidence of thyroid dysfunction.
Collapse
Affiliation(s)
- O Dalgard
- Department of Medicine, Unit of Hepatology, Aker University Hospital, Oslo, Norway.
| | | | | | | | | | | | | |
Collapse
|
14
|
Dunlop O, Bjørklund R, Bruun JN, Evensen R, Goplen AK, Liestøl K, Sannes M, Maehlen J, Myrvang B. Early psychomotor slowing predicts the development of HIV dementia and autopsy-verified HIV encephalitis. Acta Neurol Scand 2002; 105:270-5. [PMID: 12004769 DOI: 10.1034/j.1600-0404.2002.9o188.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVES- To ask if slowed motor speed predicts later human immunodeficiency virus (HIV) dementia and HIV encephalitis. METHODS- In 100 deceased acquired immunodeficiency syndrome (AIDS) patients prior results from repeated testing of the movement reaction time test were correlated with later clinical signs of HIV dementia and with neuropathological signs of HIV encephalitis. Autopsy was performed in 72 patients. RESULTS- Movement reaction time 1-2 years prior to death, or at the time of clinical AIDS diagnosis predicted both development of HIV dementia (P<0.05) and HIV encephalitis at autopsy (P<0.01). CONCLUSION- Testing for early psychomotor slowing may be used to identify patients at risk of HIV dementia and HIV encephalitis.
Collapse
Affiliation(s)
- O Dunlop
- Department of Infectious Diseases Ullevål University Hospital, Oslo, Norway.
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Bjøro K, Bell H, Myrvang B, Skaug K, Raknerud N, Sandvei P, Størseth S, Ritland S, Lund-Tønnesen S, Bucher A, Hellum KB. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study. Scand J Gastroenterol 2002; 37:344-9. [PMID: 11916198 DOI: 10.1080/003655202317284264] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND Interferon monotherapy for chronic hepatitis C virus (HCV) infection leads to sustained viral eradication in a minority of patients. However, in selected groups of patients, sustained virological response is observed in as many as 50% of patients. High initial interferon dose (induction therapy) has been reported to increase the initial response rate. We have studied the effect of interferon induction therapy in patients infected with HCV genotype 2b/3a, low viral load and no cirrhosis. METHODS A total of 71 treatment-naive HCV RNA-positive patients with biopsy-confirmed chronic hepatitis, with genotype 2b or 3a, viral load < or = 3 million copies per ml and no cirrhosis were randomized to receive either standard interferon therapy (3 MIU interferon-alpha-2a thrice weekly) for 26 weeks or 6 MIU interferon-alpha-2a daily for 4 weeks (induction group) followed by the standard dose (3 MIU thrice weekly) for 22 weeks. Those with persistent HCV RNA at 4 weeks stopped treatment. Patients were monitored for HCV RNA during and following treatment, and data were interpreted according to intention-to-treat analysis. RESULTS Viral clearance occurred more rapidly (after 4 weeks) in the induction group (33/36 = 92%) compared to the standard interferon group (21/35 = 60%) (P = 0.01). Among the initial responders, 23/33 (induction group) compared to 16/21 (standard group) were persistently HCV RNA-negative at the end of treatment. At 52 weeks (6 months' follow-up), 22/36 (61%) (induction group) compared to 10/35 (29%) (standard group) were HCV RNA-negative. Among initial responders, 22/33 (induction group) and 10/21 (standard group) achieved a sustained virological response. Among end-of-treatment responders, 22/24 (induction group) and 10/16 (standard group) were HCV RNA-negative at 6 months' follow-up (P = 0.013). CONCLUSIONS In patients infected with HCV genotype 2b/3a, low viral load and without cirrhosis, IFN induction therapy increases the initial viral clearance and reduces the risk of relapse in end-of-treatment responders. A sustained virological response was achieved in 61% of the patients receiving IFN induction therapy.
Collapse
Affiliation(s)
- K Bjøro
- Medical Dept. of National Hospital, Oslo, Norway.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Bjøro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, Døskeland B, Maeland A, Lund-Tønnesen S, Myrvang B. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002; 37:226-32. [PMID: 11843062 DOI: 10.1080/003655202753416920] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND The efficacy of interferon-alpha (IFN) induction in combination with ribavirin for chronic hepatitis C virus (HCV) infection is not known. METHODS A total of 256 treatment-naive HCV RNA-positive patients with biopsy-confirmed chronic hepatitis were enrolled in a randomized multicentre study. The patients received either standard combination therapy with 3 MIU interferon-alpha2b thrice weekly for 26 weeks or 6 MIU interferon-alpha2b daily for 4 weeks and 3 MIU 3/7 days for 22 weeks. All patients received ribavirin 1000 mg or 1200 mg (weight dependent) daily during the 26-week treatment period. Patients were monitored for HCV RNA during and following treatment. RESULTS The sustained virological response rates (26 weeks after end of treatment) were 54% and 47% for patients receiving IFN induction/ribavirin and standard IFN/ribavirin, respectively (P = 0.35). Among patients infected with genotype 1a/1b, the sustained response rates were 32% and 35%. In patients infected with genotype 2b/3a IFN induction/ribavirin led to a sustained response rate of 80% as compared to 65% in the standard combination therapy group (P = 0.073). Steatosis was more frequently seen in liver biopsies from patients infected with genotype 3a as compared to genotypes la/lb. Among genotype 1a/1b infected patients. steatosis was a highly significant predictor of failure to achieve sustained virological response. Logistic regression analysis (multivariate analysis) showed that independent predictors of sustained virological response were low age, female gender, genotype 2b/3a and HCV RNA negativity at 2 weeks. CONCLUSIONS IFN induction in combination with ribavirin does not increase the sustained virological response rate among patients infected with HCV. Absence of steatosis is an independent predictor of sustained virological response in patients infected with genotypes 1a/1b.
Collapse
Affiliation(s)
- K Bjøro
- Medical Depts., National Hospital, Aker Hospital, Central Hospital, Akershus, Oslo, Norway.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
AIM OF THE STUDY To assess the long-term hepatitis C (HCV) treatment outcome in former injecting drug users (IDUs). MATERIALS AND METHODS A long-term follow-up of 27 former IDUs who had been successfully treated for chronic hepatitis C was performed. These patients represented all IDUs who had obtained a sustained virological response in a Norwegian HCV treatment trial. The patients had been treated with interferon-alpha alone or in combination with ribavirin. At 5 years' follow-up the 27 IDUs were retested for HCV RNA and risk behaviour for HCV transmission after treatment was assessed. In the control group all 18 non-IDUs who had obtained a sustained virological response in the same treatment trial were included. RESULTS At follow-up 13-82 months (median 64) after the end of treatment only one case of probable reinfection was seen among the 27 IUDs. No reoccurrence of HCV was observed in the control group. The IDU who was HCV RNA positive at follow-up had continued injecting drugs and reported frequent needle sharing. At follow-up HCV of genotype 1a was detected in contrast to genotype 1b before treatment indicating that this patient was reinfected with HCV. A return to injecting drug use occurred in 9 (33%) of 27 IDUs. CONCLUSION The long-term outcome of HCV treatment in former IDUs was excellent. Despite frequent reinitiation of drug injection all but 1 remained HCV RNA negative.
Collapse
Affiliation(s)
- O Dalgard
- Department of Medicine, Aker University Hospital, Oslo, Norway.
| | | | | | | | | | | | | |
Collapse
|
18
|
Gjeruldsen S, Abdelnoor M, Opjordsmoen S, Myrvang B. Death rates and causes of death in cohorts of serum hepatitis patients followed up for more than 20 years. Epidemiol Infect 2001; 126:89-96. [PMID: 11293686 PMCID: PMC2869677 DOI: 10.1017/s0950268801005064] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A cohort of 214 drug addicts with serum hepatitis and a cohort of 193 hepatitis patients without drug addiction were examined in respect of death rates, causes of death and a number of risk factors for reduced survival. The death rate was significantly higher among the drug addicts than among non-addicts. The annual mortality rate was 1.5% in the drug addict group and 0.7% in the non-addict group. The highest relative risk of death was 860 for female drug addicts in age group 15-24 compared to females of the same age in the general population. The most prevalent cause of death in the drug addict group was drug overdose (53%), whereas in the other group 66% died from various somatic diseases. Hepatitis or complications of viral hepatitis played no role as cause of death among the drug addicts, and infections as a whole were also responsible for very few deaths. For male drug addicts, imprisonment before admission and leaving hospital without the doctors' permission were risk factors for early death.
Collapse
Affiliation(s)
- S Gjeruldsen
- Department of Infectious Diseases, Ullevål Hospital, Oslo, Norway
| | | | | | | |
Collapse
|
19
|
Abstract
Erythromelalgia is a clinical syndrome characterized by burning pain in the extremities together with erythema and increased skin temperature. Typically, the patients experience relief from cold, and aggravation from warmth. Symptoms are hypothesized to be caused by arteriovenous shunting and reduced nutritive skin capillary perfusion with corresponding tissue hypoxia. Erythromelalgia is most often primary, but may be secondary to a wide variety of diseases. We report erythromelalgia in a patient with acquired immune deficiency syndrome (AIDS). At peak pain intensity he actively cooled hands and feet for more than 12 h/day. Many doctors handling human immunodeficiency virus/AIDS patients are unfamiliar with erythromelalgia, and the condition can easily be overlooked, especially the more common milder cases.
Collapse
Affiliation(s)
- C Mørk
- Department of Dermatology, The National Hospital, University of Oslo, Norway.
| | | | | | | |
Collapse
|
20
|
Brubakk O, Myrvang B. [Non-practical guidelines?]. Tidsskr Nor Laegeforen 2000; 120:3196. [PMID: 11109372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
|
21
|
Myrvang B, Godal T. [WHO's malaria program Roll Back Malaria]. Tidsskr Nor Laegeforen 2000; 120:1661-4. [PMID: 10901078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
Abstract
Malaria is one of the main health problems in the world with 300-500 millions cases yearly and about one million deaths, mainly children in Sub-Saharan Africa. In the 1990s the malaria problem in Africa has increased, although we have methods to control the disease. In 1998 the new secretary general of WHO, Gro Harlem Brundtland, established the Roll Back Malaria programme, with the aim to markedly reduce malaria morbidity and mortality. Governments in malaria-affected countries have to take the lead in Roll Back Malaria. Their health systems must be improved and malaria control integrated into the general health system, and the methods available for prevention and treatment have to be intensified and improved. At the same time, Roll Back Malaria will encourage and promote malaria research which hopefully will result in new medicines, vaccines and other tools which will improve the chances of reducing malaria-related deaths and suffering. Roll Back Malaria is a cabinet project within the WHO, and the organisation has a key role as manager, co-ordinator and monitor of the project. However, it depends for resources on international support and commitment from other UN bodies, the World Bank, governments in the western world, pharmaceutical industry, philanthropists and other sources. At present an optimistic view prevails, and the preliminary aim, to halve the malaria mortality by the year 2010, seems realistic even with the control methods of today. However, if research efforts result in new and better tools to combat the disease, the task will definitely be easier.
Collapse
Affiliation(s)
- B Myrvang
- Infeksjonsmedisinsk avdeling Ullevål sykehus, Oslo
| | | |
Collapse
|
22
|
Myrvang B. [Malaria in Norway--diagnosis, treatment and prevention]. Tidsskr Nor Laegeforen 2000; 120:1648-52. [PMID: 10901075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
Abstract
The paper describes and discusses procedures and problems related to diagnostics, therapy and prophylaxis of malaria in Norway. A high degree of suspicion in physicians evaluating febrile travellers is of the utmost importance. The clinical symptoms and findings are initially rather unspecific, with fever and fever related symptoms. A definite diagnosis is made by the demonstration of malaria parasites in thin and thick blood smears, which is best performed by an infectious disease physician. Before treatment is started, it is important to determine whether the patient is infected with Plasmodium falciparum or with one of the more benign malaria species. If this is difficult microscopically, a test that detects P. falciparum antigen in blood may be useful in some cases. The therapy of benign malaria is still chloroquine plus primaquine; most patients with malaria falciparum can be routinely treated with mefloquine. Cases of complicated falciparum malaria, usually due to delayed diagnosis and start of treatment, require extensive and sophisticated treatment, usually including parenteral treatment with quinine. Prophylaxis consists of prevention of mosquito bites and chemoprophylaxis; the importance of avoiding bites should never be underestimated. A more widespread use of mefloquine among travellers to Africa is the most important change in chemoprophylaxis in recent years. Finally the article discusses possible improvements in diagnostic procedure, therapy and chemoprophylaxis.
Collapse
Affiliation(s)
- B Myrvang
- Infeksjonsmedisinsk avdeling Ullevål sykehus, Oslo
| |
Collapse
|
23
|
Rønning EJ, Myrvang B, Jensenius M. [Falciparum malaria in Oslo and Akerhus]. Tidsskr Nor Laegeforen 2000; 120:1658-60. [PMID: 10901077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
Abstract
BACKGROUND Imported falciparum malaria in an increasingly frequent health problem in many areas in which it is not endemic. Complications are commonly seen, and reported case-fatality rates may exceed 3%. MATERIAL AND METHODS The study is a medical chart-based retrospective study of all cases of falciparum malaria diagnosed in Oslo and Akershus counties, south-eastern Norway, 1988-1997. RESULTS We identified 232 diagnosed cases; of these, records were available for 222 cases (95%). The incidence rate almost quadrupled during the study period. The two largest groups were immigrants visiting their country of origin (35%) and Norwegian tourists (29%). 95% of the cases were infected in Sub-Saharan Africa. There were no fatal cases, and only eight cases (3.6%) developed complicated falciparum malaria. In a statistical analysis, the following factors were found to be significantly associated with complicated disease: higher age, noncompliance to recommended chemoprophylaxis in assumed non-immune subjects, prolonged doctor's delay and prolonged diagnostic delay. INTERPRETATION The study suggests that complications in imported falciparum malaria may largely be prevented by a high rate of chemoprophylaxis compliance in non-immune travellers and a high awareness of this possibility among physicians evaluating febrile travellers from endemic areas.
Collapse
Affiliation(s)
- E J Rønning
- Infeksjonsmedisinsk avdeling Ullevål sykehus, Oslo
| | | | | |
Collapse
|
24
|
Liestøl K, Kvittingen EA, Rootwelt H, Dunlop O, Goplen AK, Pedersen JC, Brorson SH, Børresen-Dale AL, Myrvang B, Maehlen J. Association between apolipoprotein E genotypes and cancer risk in patients with acquired immunodeficiency syndrome. Cancer Detect Prev 2000; 24:496-9. [PMID: 11129992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/15/2023]
Abstract
The apolipoprotein E (apoE) genotype was determined in 197 deceased acquired immunodeficiency syndrome (AIDS) patients treated at Ullevaal Hospital in Oslo, Norway. A full autopsy had been performed on all. Cancer had developed in 71 individuals, mainly lymphomas (46) and Kaposi's sarcomas (18). The apoE genotype distribution was consistent with Hardy-Weinberg equilibrium, and allele frequencies were in the typical Scandinavian range (6.9% apoE2; 75.6% apoE3; and 17.5% apoE4). Cancer cases had a significantly higher frequency of apoE4 alleles than noncancer cases (24.6% and 13.5%, respectively) and a lower frequency of apoE2 alleles (3.5% versus 8.7%). Background factors, such as survival from AIDS diagnosis, could not explain these differences. Our study thus indicates that apoE genotype affects the development of cancers among AIDS patients.
Collapse
Affiliation(s)
- K Liestøl
- Department of Informatics, University of Oslo, Norway
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Jensenius M, Hasle G, Henriksen AZ, Vene S, Raoult D, Bruu AL, Myrvang B. African tick-bite fever imported into Norway: presentation of 8 cases. Scand J Infect Dis 1999; 31:131-3. [PMID: 10447320 DOI: 10.1080/003655499750006155] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
We report on 8 Norwegian travellers to Southern Africa with African tick-bite fever (ATBF), a recently described spotted fever group rickettsiosis. All patients had acute flu-like symptoms and developed I or multiple inoculation eschars. The patients were treated with either doxycycline or ciprofloxacin, and all recovered. The diagnosis of ATBF was confirmed by the detection of specific IgM antibodies to Rickettsia africae by microimmunofluoroscence in convalescent-phase serum samples.
Collapse
Affiliation(s)
- M Jensenius
- Department of Internal Medicine, Aker University Hospital, Oslo, Norway
| | | | | | | | | | | | | |
Collapse
|
26
|
Hem E, Small T, Opjordsmoen S, Myrvang B. [Neurosyphilis--still a relevant differential diagnosis]. Tidsskr Nor Laegeforen 1999; 119:2469-71. [PMID: 10425898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023] Open
Abstract
Syphilis, in all stages, is almost eradicated in Norway. Since 1993, only six to 17 patients have been registered per year. However, syphilis rates are increasing in some of Norway's neighbouring countries, e.g. Russia and the Baltic countries. Physicians must be aware of the disease. We report three patients admitted to an emergency psychiatric ward in Oslo, diagnosed with neurosyphilis during 1994-97. Doctor's delay in diagnosing was respectively seven and fifteen months for two of these patients. The diagnosis is difficult, for many reasons: The disease is rare; it can mimic several other diseases; incidental partial treatment with antibiotics given for other disorders may complicate the clinical picture; it may be difficult to obtain a reliable history; and new clinical pictures ("formes frustes") may occur. The traditional syphilis screening is not recommendable, but physicians' awareness and a low threshold for requiring syphilis serology tests is important in order to get an early diagnosis of one of the few curable psychiatric disorders.
Collapse
Affiliation(s)
- E Hem
- Avdeling for akuttpsykiatri, Ullevål sykehus, Oslo
| | | | | | | |
Collapse
|
27
|
Jensenius M, Rønning EJ, Blystad H, Bjørneklett A, Hellum KB, Bucher A, Håheim LL, Myrvang B. Low frequency of complications in imported falciparum malaria: a review of 222 cases in south-eastern Norway. Scand J Infect Dis 1999; 31:73-8. [PMID: 10381222 DOI: 10.1080/00365549950161925] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
We performed a retrospective study of 222 cases of falciparum malaria diagnosed in Oslo and Akerhus counties, Norway, from January 1988 to December 1997. Except for 12 cases, all had acquired the disease in sub-Saharan Africa. Sixty-four (28.8%) cases occurred in assumed non-immune individuals; of these, 41 (64.1%) were compliant to recommended antimalarial chemoprophylaxis. The mean time lag from first symptom to diagnosis (total diagnosis delay) was 4.6 d (median 3 d, range 0-30 d) and the mean time from presentation to diagnosis (doctor's delay) was 1.3 d (median 0 d, range 0-25 d). There were no fatal cases, and only 8 (3.6%) had a complicated course. The following factors were significantly associated with development of complicated disease: higher age, non-immunity combined with chemoprophylaxis non-compliance, prolonged doctor's delay and prolonged total diagnosis delay (p < or = 0.05). Our data suggest that complicated disease in imported falciparum malaria may largely be prevented by high chemoprophylaxis compliance rates in non-immune travellers and a high index of suspicion in physicians evaluating febrile travellers.
Collapse
Affiliation(s)
- M Jensenius
- Department of Internal Medicine, Aker University Hospital, Norway
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Bell H, Hellum K, Harthug S, Myrvang B, Ritland S, Maeland A, von der Lippe B, Bjøro K, Skaug K, Gutigard BG, Raknerud N, Simmonds P. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group. Scand J Gastroenterol 1999; 34:194-8. [PMID: 10192200 DOI: 10.1080/00365529950173087] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND Preliminary results from combination therapy with interferon-alpha and ribavirin (IFN/Rib) in patients with chronic hepatitis C have been promising, with up to 50% sustained hepatitis C virus (HCV) RNA response. The aim of this study was to investigate whether a sustained HCV RNA response could be obtained with combination therapy in patients who were non-responders or relapsers after IFN treatment. METHODS In a multicenter study we randomized 53 HCV RNA-positive patients into 2 treatment groups. They all had biopsy-confirmed chronic hepatitis C, and all were recruited from a previous IFN study: 26 were previous non-responders and 27 responders with relapse. Group A received interferon-alpha2a, 4.5 MIU thrice weekly for 6 months, and group B received ribavirin, 1000-1200 mg/day, in combination with the same dose of interferon-alpha2a for 6 months. Median Knodell index was 5.0 in both groups. Genotype 1 was found in 24 (45%), type 2 in 3 (6%), and type 3 in 26 (49%). RESULTS Sustained clearance of HCV viremia 6 months after interferon-alpha2a treatment stop was obtained in 12 of 53 patients (23%): 6 of 27 in the IFN group (22%) and 6 of 26 (23%) in the IFN/Rib group (NS). Nine of 27 (33%) former responders with relapse, compared with 3 of 26 (12%) non-responders, obtained a sustained HCV RNA response (P = 0.054). In previous relapse patients sustained loss of viremia was more frequent in genotype 3 (50%) than in genotype 1 (11%) patients (P = 0.022). CONCLUSIONS In a group of previous IFN-alpha2a-treated chronic HCV patients we obtained a similar sustained clearance of viremia when retreated either with IFN-alpha2a alone or with a combination of IFN-alpha2a and ribavirin for 6 months. Previous relapse patients with HCV genotype 3 obtained sustained loss of viremia significantly more often (50%) than type-patients (11%). Previous IFN responders with relapse responded better than previous non-responders.
Collapse
Affiliation(s)
- H Bell
- Dept. of Medicine, Aker University Hospital, Oslo, Norway
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Tangen JM, Berentsen S, Dahl IM, Ly B, Myrvang B. [Empirical antibiotic treatment of patients with acute myelogenous leukemia]. Tidsskr Nor Laegeforen 1999; 119:35-8. [PMID: 10025202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023] Open
Abstract
All febrile episodes (a total of 276) which occurred in 85 patients with acute myelogenous leukaemia treated in four Norwegian centres during the period 1990-1994 were studied retrospectively in order to assess the efficacy of antibiotic treatment. 72% of these episodes were initially treated with benzyl penicillin and aminoglycoside (standard treatment), while alternative empirical treatment was given in the remaining cases. The treatment was successful in 94% of the febrile episodes initially treated with standard treatment and in 96% of the episodes which received alternative antibiotics. For both types of treatment, a change to second line antibiotic regimen was made for various reasons in a majority of cases. The combination benzyl penicillin and aminoglycoside seems to be a safe empirical treatment for febrile neutropenia in patients with acute myelogenous leukaemia in our treatment centres, provided that the treatment is modified in patients with unsatisfactory clinical response.
Collapse
|
30
|
Lundin KE, Selbekk BH, Myrvang B, Løberg EM. [Cytomegalovirus as the cause of toxic dilatation of the colon]. Tidsskr Nor Laegeforen 1998; 118:3277-9. [PMID: 9772815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
Abstract
Toxic dilatation of the colon is sometimes a complication which occurs during exacerbations of inflammatory bowel disease. It often requires immediate surgical intervention. We describe here a male patient with known ulcerative colitis who was investigated for fever of unknown cause, diarrhoea, and general illness. Upon admission he had only modest symptoms of colitis and received no immunosuppressive treatment. The condition worsened considerably, and subsequent colonoscopy demonstrated widespread lesions compatible with viral disease, but not with ulcerative colitis. Antiviral treatment for cytomegalovirus was started immediately, but progression of the condition with toxic dilatation called for a rapid colectomy. Histological examination showed widespread lesions compatible with cytomegalovirus infection. This clinical picture is rarely seen in immunocompetent patients.
Collapse
Affiliation(s)
- K E Lundin
- Gastromedisinsk avdeling, Ullevål sykehus, Oslo
| | | | | | | |
Collapse
|
31
|
Jensenius M, Myrvang B, Størvold G, Bucher A, Hellum KB, Bruu AL. Herpes simplex virus type 2 DNA detected in cerebrospinal fluid of 9 patients with Mollaret's meningitis. Acta Neurol Scand 1998; 98:209-12. [PMID: 9786620 DOI: 10.1111/j.1600-0404.1998.tb07296.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We present clinical and virological data on 9 patients, 7 women and 2 men aged 31-56 years, with recurrent aseptic meningitis (Mollaret's meningitis). Polymerase chain reaction detected Herpes simplex virus type 2 DNA in cerebrospinal fluid samples from all patients collected during their latest attacks of meningitis. Six patients had no history of genital herpes. Only 1 patient was offered prophylactic antiviral treatment during the study period (45 months).
Collapse
Affiliation(s)
- M Jensenius
- Department of Internal Medicine, Aker University Hospital, Oslo, Norway
| | | | | | | | | | | |
Collapse
|
32
|
Jensenius M, Myrvang B. [Imported fever. A diagnostic challenge]. Nord Med 1998; 113:107-11. [PMID: 9579092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Fevers without distinguishing symptoms in persons who have visited tropical or subtropical areas is an increasing health problem in most western countries. The condition may be caused by several different microbes, but among cases diagnosed in Norway five infections dominate: falciparum malaria, vivax malaria, typhoid fever, paratyphoid fever and dengue fever. Primary measures should be taken against immediate life-threatening diseases e.g. typhoid fever and falciparum malaria.
Collapse
|
33
|
Jarvis LM, Bell H, Simmonds P, Hawkins A, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B, von der Lippe B, Raknerud N, Skaug K. The effect of treatment with alpha-interferon on hepatitis G/GBV-C viraemia. The CONSTRUCT Group. Scand J Gastroenterol 1998; 33:195-200. [PMID: 9517532 DOI: 10.1080/00365529850166941] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND Hepatitis G virus (HGV) or GBV-C is frequently detected in patients co-infected with hepatitis C virus (HCV). This study investigated host and virologic factors influencing the response to HGV/GBV-C to alpha-interferon treatment. METHODS HGV/GBV-C was detected and quantified by nested polymerase chain reaction. The influence of variables such as liver biopsy appearance, liver function abnormalities, and response of HCV to interferon treatment was monitored. RESULTS Fourteen of the 25 HGV/GBV-C-infected patients treated with interferon (3-6 MIU three times a week for 6 months) became non-viraemic during treatment, although all relapsed after treatment withdrawal at 6 months, with no net change in virus load between 0 and 12 months. CONCLUSIONS Predictive factors for clearance of HGV/GBV-C viraemia by interferon were pre-treatment severity of liver disease (median Knodell score of 4, compared with 7 for non-responders; P = 0.030) and alanine aminotransferase levels (median, 114, 182 for non-responders; P = 0.039). Clearance was associated with the treatment response of HCV. Nine of 13 who cleared HGV/GBV-C also cleared HCV, compared with 3 of 11 HGV/GBV-C non-responders; P = 0.05). The shared susceptibility of HGV/GBV-C and HCV to interferon treatment suggests a link between the mechanism of clearance of the two viruses.
Collapse
Affiliation(s)
- L M Jarvis
- Dept. of Medical Microbiology, University of Edinburgh, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Jensenius M, Myrvang B. [Imported fever]. Tidsskr Nor Laegeforen 1998; 118:402-6. [PMID: 9499729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Fevers without distinguishing symptoms in persons who have visited tropical or subtropical areas is an increasing health problem in most western countries. The condition may be caused by several different microbes, but among cases diagnosed in Norway five infections dominate: falciparum malaria, vivax malaria, typhoid fever, paratyphoid fever, and dengue fever. In this article the authors give an overview of current microbes, and present diagnostic guidelines on how to handle cases of imported fevers in Norway. Primary measures should be taken against immediate life-threatening diseases, e.g. typhoid fever and falciparum malaria.
Collapse
|
35
|
Jensenius M, Myrvang B, Størvold G. [Serous meningitis associated with primary genital herpes infection]. Tidsskr Nor Laegeforen 1997; 117:2316-8. [PMID: 9265274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Aseptic meningitis is not an uncommon complication to primary genital herpes infection caused by herpes simplex virus type 2 (HSV-2). Compared with other types of viral meningitis, HSV-2-meningitis is associated with a significant rate of neurological complications in the acute stage. In addition, some patients will suffer from recurrent aseptic meningitis (Mollaret's meningitis) later. We describe six patients, five women and one man, age 26-35 years, with aseptic meningitis caused by HSV-2. All the patients showed serological evidence of primary herpes infection (negative HSV-IgG and/or positive HSV-IgM in serum samples). Polymerase chain reaction detected HSV-2 in cerebrospinal fluid in all five of five cases, while virus cultures were positive in two of the six cases. Only three patients showed clinical signs of simultaneous genital herpes infection. One patient, a 28-year-old female, developed transient autonomic nervous system dysfunction with urinary retention, constipation, and neuralgic pain in the buttocks, perineum and lower limbs. 13 months later she was hospitalised for a genital herpes infection with headache, parestesia and fever, but spinal fluid examination showed no abnormality.
Collapse
Affiliation(s)
- M Jensenius
- Medisinsk avdeling, Lovisenberg Diakonale Sykehus, Oslo
| | | | | |
Collapse
|
36
|
Jenseuius M, Myrvang B, Størvold G. [Mollaret meningitis. Is the riddle finally solved?]. Tidsskr Nor Laegeforen 1997; 117:2319-21. [PMID: 9265275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Mollaret's meningitis is characterised by recurrent aseptic meningitis in otherwise healthy persons. It has recently been shown that most cases are caused by herpes simplex virus type 2 (HSV-2). In this article we describe five women, age 33-57 years, with altogether 12 episodes of virus-culture negative aseptic meningitis, where polymerase chain reaction detected HSV-2 in samples of cerebrospinal fluid. Only three patients had a medical history of previous genital herpes infection. None of our patients has been offered prophylactic antiviral treatment.
Collapse
Affiliation(s)
- M Jenseuius
- Medisinsk avdeling, Lovisenberg Diakonale Sykehus, Oslo
| | | | | |
Collapse
|
37
|
Abstract
The effect of apolipoprotein E genotypes on the occurrence of HIV dementia and HIV encephalitis was studied in a sample of 132 AIDS patients in whom clinical data on dementia was available and full autopsy had been performed. There was no statistically significant correlation between risk of HIV dementia or HIV encephalitis in relation to apolipoprotein E genotypes, even after correction for length of survival with AIDS and antiretroviral treatment.
Collapse
Affiliation(s)
- O Dunlop
- Department of Infectious Diseases, Ullevål University Hospital, Oslo, Norway
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Myrvang B. [Malaria in Norway]. Tidsskr Nor Laegeforen 1997; 117:984-5. [PMID: 9103014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Affiliation(s)
- B Myrvang
- Infeksjonsmedisinsk avdeling Ulleväl sykehus, Oslo
| |
Collapse
|
39
|
Gundersen SG, Rostrup M, von der Lippe E, Platou ES, Myrvang B, Edwards G. Halofantrine-associated ventricular fibrillation in a young woman with no predisposing QTc prolongation. Scand J Infect Dis 1997; 29:207-8. [PMID: 9181664 DOI: 10.3109/00365549709035889] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- S G Gundersen
- Department of Infectious Diseases, Ullevaal Hospital, University of Oslo, Norway
| | | | | | | | | | | |
Collapse
|
40
|
Bell H, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B, von der Lippe B, Raknerud N, Skaug K, Gutigard BG, Skjaerven R, Prescott LE, Simmonds P. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group. Scand J Infect Dis 1997; 29:17-22. [PMID: 9112292 DOI: 10.3109/00365549709008658] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Patients with chronic hepatitis C respond differently when treated with interferon. We randomized 116 patients with chronic hepatitis C in order to compare two dosage regimens of recombinant interferon alpha 2a:3 MIU x 3 per week for 6 months (arm A) or 6 MIU x 3 per week for 3 months and then 3 MIU x 3 per week for 3 months (arm B). There were no significant differences concerning outcome between the two dose regimens: sustained clearance of HCV viremia 6 months after the end of treatment was obtained in 12/59 (20%) in group A compared with 18/57 (32%) in group B (p = 0.24). In patients with genotype 1a, 4/31 (13%), in genotype 1b, none of 9 (0%), 9/15 (60%) in genotype 2, and 17/58 (29%) in genotype 3, showed sustained clearance of HCV viremia 6 months after the end of treatment (p = 0.002). In a stepwise logistic regression analysis, only pretreatment viral load (p = 0.0001), genotype (p = 0.001) and age (p = 0.04) were identified as independent predictors of sustained clearance of HCV viremia. Liver histology as assessed by Knodell index was significantly improved in patients with sustained HCV RNA response 6 months after the end of treatment (5.2 +/- 2.2 vs 2.6 +/- 2.2, p < 0.001), but not in responders with relapse or in non-responders. In conclusion, stepwise logistic regression analysis showed that viral load, HCV genotype and age were the only independent predictors for sustained HCV RNA response.
Collapse
Affiliation(s)
- H Bell
- Department of Medicine, Aker University Hospital, Oslo, Norway
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Schrumpf E, Bjøro K, Bell H, Harthug S, Hellum KB, Myrvang B, Maeland A, Ritland S. [Treatment of hepatitis C]. Tidsskr Nor Laegeforen 1996; 116:1792-4. [PMID: 8693463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Hepatitis C virus (HCV) has been a major cause of post transfusion hepatitis, and is still an important cause of chronic liver disease throughout the world. How to treat patients with chronic HCV infection has been brought into focus in recent years, and a substantial amount of data has been obtained about the development of hepatitis C with and without treatment. This survey considers the diagnosis of hepatitis C, and present treatment modalities and their potential. The patients most likely to respond to treatment are described, and the authors finally discuss why treatment of hepatitis C still should take place in controlled studies.
Collapse
Affiliation(s)
- E Schrumpf
- Medisinsk avdeling A Rikshospitalet, Oslo
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Dunlop O, Rootwelt V, Sannes M, Goplen AK, Abdelnoor M, Skaug K, Baklien K, Skar A, Melby K, Myrvang B, Bruun JN. Risk of toxoplasmic encephalitis in AIDS patients: indications for prophylaxis. Scand J Infect Dis 1996; 28:71-3. [PMID: 9122637 DOI: 10.3109/00365549609027153] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
To establish the indications for primary prophylaxis against toxoplasmic encephalitis in the Norwegian HIV-positive population, we estimated the incidence of toxoplasmic encephalitis, and related the degree of immunodeficiency and the presence of IgG antibodies against Toxoplasma gondii (T. gondii) to the development of toxoplasmic encephalitis. This retrospective study includes all HIV-positive patients at our hospital from April 1983 to October 1994 (n = 705). A total of 238 patients had AIDS, which represents almost 90% of all AIDS patients in Oslo. Autopsy was done in over 70% of the patients who died during this period; 19 patients developed toxoplasmic encephalitis (8.0%). The median CD4 cell count was 75 x 10(6) cell/I (range 0-280) at the time of diagnosis of toxoplasmic encephalitis. T. gondii serology was studied in 698 (99.0%) of the patients, and was found positive for 17.8%. Of the patients with toxoplasmic encephalitis 18/19 had IgG antibodies against T. gondii and of the 40 AIDS patients who had anti-T. gondii IgG, 18 (45%) developed toxoplasmic encephalitis. We conclude that there is indication for prophylactic treatment of HIV positive patients who have IgG antibodies against T. gondii and who have fewer than 200 x 10(6) CD4 cells/I.
Collapse
Affiliation(s)
- O Dunlop
- Department of Infectious Diseases, Ulleval University Hospital, Oslo, Norway
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Bell H, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B, von der Lippe B, Raknerud N, Skaug K, Prescott L, Simmonds P. Prevalence of hepatitis C genotypes among patients with chronic hepatitis C in Norway. Construct Group. Scand J Infect Dis 1996; 28:357-9. [PMID: 8893398 DOI: 10.3109/00365549609037919] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Among 116 patients with biopsy-confirmed chronic hepatitis C (Riba 2 or Riba 3 positive) in a multicenter study in southern Norway on interferon, we determined hepatitis C virus genotype by restriction fragment length polymorphism (RFLP) of the 5' NCR. The RFLP method was supplemented by and compared with a serological typing method based on the detection of type-specific antibody to peptide from the NS-4 region. A total of 102/106 (96%) patient sera showed detectable type-specific antibody to NS-4 peptides and corresponded in all cases, except two, to the genotype detected by polymerase chain reaction. Combining the results from RFLP genotyping and serotyping, genotype 1 was found in 40 (35%) (27 with 1a and 10 with 1b, 3 subtypes not determined), genotype 2 in 15 (13%) (subtype 2b in 14 and 1 subtype not determined), and genotype 3 in 58 (50%) of patients. The low mean age of the patients (34 years), the low prevalence of cirrhosis (3.5%), the short duration of the disease, and a high prevalence of intravenous-drug abusers may account for the low prevalence of infection with genotype 1b (9%). The epidemiological features of hepatitis C patients are markedly different from patient groups described in southern Europe in terms of risk factors, age, and genotype distribution.
Collapse
Affiliation(s)
- H Bell
- Department of Medicine, Aker University Hospital, Oslo, Norway
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Gundersen SG, Myrvang B. [Specific intracranial infections]. Tidsskr Nor Laegeforen 1995; 115:2434. [PMID: 7667862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
|
45
|
Abstract
In an attempt to develop better methods for diagnosis, screening and serial assessment of HIV-1-associated cognitive/motor complex, we have added a motor component to tests of reaction time, defining the new parameter as total reaction time. Thirty-four non-drug-using, HIV-positive men underwent four different tests of total reaction time. All four tests reached a level of statistical significance, both for a group of patients with early disease and for a group of patients with symptoms, compared with a control group. Total reaction time had a better discriminatory ability than standard reaction time, particularly for patients with early disease. It is suggested that neuropsychological studies of HIV-1-associated cognitive/motor complex should include tests of total reaction time.
Collapse
Affiliation(s)
- O Dunlop
- Department of Infectious Diseases, Ullevaal University Hospital, Oslo, Norway
| | | | | | | |
Collapse
|
46
|
|
47
|
Abstract
In an attempt to develop a short neuropsychological test battery five different tests of reaction time were assessed according to their ability to discriminate between HIV seropositive men and healthy controls. In all tests a patient group with clinical symptoms was slower than the control group. In the complex reaction time test, which has a large cognitive aspect, even a clinically "asymptomatic" group was slower than the control group. The movement test, a new test with a large motor component, identified most slow responders, defining approximately half of the patients with clinical symptoms and one third of the "asymptomatic" patients as such. A test battery consisting of three tests is suggested for serial assessment and screening.
Collapse
Affiliation(s)
- O Dunlop
- Department of Infectious Diseases, Ullevaal University Hospital, Oslo, Norway
| | | | | | | |
Collapse
|
48
|
Midtvedt K, Myrvang B. [Antibiotic prevention in permanent pacemaker implantation in Norway]. Tidsskr Nor Laegeforen 1991; 111:1106-7. [PMID: 2024255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
In Norway 33 hospitals perform permanent pacemaker implantations. 21 hospitals do not use prophylactic antibiotics as a routine. These hospitals implant approximately 600 pacemakers per year. 12 hospitals use prophylactic antibiotics. These hospitals implant approximately 400 pacemakers per year. None of the hospitals using antibiotics follow the same regime.
Collapse
Affiliation(s)
- K Midtvedt
- Medisinsk avdeling, Ullevål sykehus, Oslo
| | | |
Collapse
|
49
|
Dunlop O, Bruun JN, Myrvang B, Fagerhol MK. Calprotectin in cerebrospinal fluid of the HIV infected: a diagnostic marker of opportunistic central nervous system infection? Scand J Infect Dis 1991; 23:687-9. [PMID: 1815329 DOI: 10.3109/00365549109024294] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The calprotectin level in the cerebrospinal fluid (CSF) of 15 HIV positive patients with symptoms from the central nervous system (CNS) was measured. All 5 patients with opportunistic infections had levels above the reference range and all 10 patients with HIV associated encephalopathy had levels within the reference range. Thus, the calprotectin level in CSF can be of diagnostic value in differentiating between HIV associated encephalopathy and opportunistic infection in the HIV positive patient with symptoms from the CNS.
Collapse
Affiliation(s)
- O Dunlop
- Department of Infectious Diseases, Ullevaal University Hospital, Oslo, Norway
| | | | | | | |
Collapse
|
50
|
Linnestad P, Myrvang B, Ritland S, Bergan A, Valnes K, Holst JJ. [Glucagon producing tumors of the pancreas. A case report and literature review]. Tidsskr Nor Laegeforen 1983; 103:1520-2. [PMID: 6314588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
|